Literature DB >> 24733459

Very-high-dose caspofungin combined with voriconazole to treat central nervous system aspergillosis: substantial penetration of caspofungin into cerebrospinal fluid.

François Réminiac1, Romain Sonneville2, Laurent Massias3, Christian Chochillon4, Michel Wolff2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24733459      PMCID： PMC4068458          DOI： 10.1128/AAC.02719-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis.

Authors:  Amy M Flattery; Emily Hickey; Charles J Gill; Mary Ann Powles; Andrew S Misura; Andrew M Galgoci; Joan D Ellis; Rena Zhang; Punam Sandhu; John Ronan; George K Abruzzo
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis.

Authors:  S Schwartz; A Reisman; P F Troke
Journal:  Infection       Date:  2011-04-22       Impact factor: 3.553

3.  A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid.

Authors:  Shu Okugawa; Yasuo Ota; Keita Tatsuno; Kunihisa Tsukada; Satoshi Kishino; Kazuhiko Koike
Journal:  Scand J Infect Dis       Date:  2007

Review 4.  Efficacy and safety of current drug therapies for invasive aspergillosis.

Authors:  Friederike Traunmüller; Martin Popovic; Karl-Heinz Konz; Freyja-Maria Smolle-Jüttner; Christian Joukhadar
Journal:  Pharmacology       Date:  2011-10-06       Impact factor: 2.547

5.  Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.

Authors:  Karl V Clemons; Julie A Schwartz; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

6.  Cerebral aspergillosis in adult critically ill patients: a descriptive report of 10 patients from the AspICU cohort.

Authors:  Herbert Spapen; Jerrold Spapen; Fabio S Taccone; Wouter Meersseman; Jordi Rello; George Dimopoulos; Pierre-Emmanuel Charles; Ratna Rao; Marcos Pérez; Claude Martin; Dirk Vogelaers; Stijn I Blot
Journal:  Int J Antimicrob Agents       Date:  2013-11-15       Impact factor: 5.283

7.  Cerebral aspergillosis in the critically ill: two cases of successful medical treatment.

Authors:  Stephan Ehrmann; Frédéric Bastides; Valérie Gissot; Emmanuelle Mercier; Pascal Magro; Eric Bailly; Annick Legras
Journal:  Intensive Care Med       Date:  2005-03-22       Impact factor: 17.440

8.  Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance.

Authors:  F Suarez; O Lortholary; S Buland; M T Rubio; D Ghez; V Mahé; G Quesne; S Poirée; A Buzyn; B Varet; P Berche; M E Bougnoux
Journal:  J Clin Microbiol       Date:  2008-09-24       Impact factor: 5.948

Review 9.  Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases.

Authors:  Spinello Antinori; Mario Corbellino; Luca Meroni; Federico Resta; Salvatore Sollima; Massimo Tonolini; Anna Maria Tortorano; Laura Milazzo; Lorenzo Bello; Elisa Furfaro; Massimo Galli; Claudio Viscoli
Journal:  J Infect       Date:  2012-11-21       Impact factor: 6.072
  9 in total
  2 in total

Review 1.  Chronic Meningitis.

Authors:  Kiran T Thakur; Michael R Wilson
Journal:  Continuum (Minneap Minn)       Date:  2018-10

2.  Antifungal Drugs: Special Problems Treating Central Nervous System Infections.

Authors:  Elizabeth Dodds Ashley
Journal:  J Fungi (Basel)       Date:  2019-10-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.